SI-BONE, Inc. (SIBN)
NASDAQ • Healthcare
Last close at October 23, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, SI-BONE, Inc. currently loses $7.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 2
in 8 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Next report — what to expect
SI-BONE, Inc. (SIBN) is scheduled to report earnings on November 9, 2026. Wall Street’s next-period consensus calls for EPS of -$0.13 on revenue of $55.3 million. For trailing context, revenue grew +15.2% year over year last quarter. The company has beaten EPS in 8 of 8 most recent quarters.
About SI-BONE, Inc.
SI-BONE, Inc. develops and markets implantable solutions for musculoskeletal conditions in the sacropelvic region. Listed on the NASDAQ as SIBN, the company operates in medical devices and generated $200.9 million of revenue in FY2025. Its business centers on minimally invasive implants used to treat sacroiliac joint disorders, pelvic trauma, and related spine conditions.
Today's Snapshot
SIBN ended the day slightly lower at 21.48, while its sector was weaker. SIBN closed within 1.9% of its 52-week high of 21.89. SIBN is due to report earnings on 2 November.
Trading Volume
Below 10d avg (580.4K)
447.6K
vs S&P 500 Today
Moderate Outperformance
+0.15%
Updated: October 23, 2026 at 20:12 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$17.38 - $20.44Buy
- RSI (14)68.50Neutral
- Stochastic %K (14, 3, 3)91.77Sell
- MACD Level (12, 26)0.61Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.